Deregulated AJAP1/β-catenin/ZEB1 signaling promotes hepatocellular carcinoma carcinogenesis and metastasis.
Jihua Han,Changming Xie,Tiemin Pei,Jiabei Wang,Yaliang Lan,Kaihua Huang,Yifeng Cui,Fengyue Wang,Jiewu Zhang,Shangha Pan,Yingjian Liang,Tongsen Zhen,Ruipeng Song,Boshi Sun,Yuejin Li,Huawen Shi,Guangchao Yang,Xirui Liu,Mingxi Zhu,Yan Wang,Keyu Li,Yao Liu,Fanzheng Meng,Fei Liao,Xianzhi Meng,Xuehui Hong,Lianxin Liu
DOI: https://doi.org/10.1038/cddis.2017.126
2017-01-01
Abstract:Adherens junctions-associated protein 1 (AJAP1) is an integral membrane protein that is thought to function as a tumor suppressor in various malignancies. Downregulation of AJAP1 mRNA levels may predict recurrence in hepatocellular carcinoma (HCC) patients, but the underlying molecular mechanism is unknown. This was addressed in the present study by examining the role of AJAP1 in HCC cell proliferation, migration, and invasion in vitro as well as in human specimens and mouse xenograft model. We found that AJAP1 expression was reduced in HCC cells and human HCC tissue, which was associated with metastasis. AJAP1 overexpression inhibited HCC progression and metastasis, while its silencing had the opposite effect both in vitro and in vivo. Furthermore, AJAP1 blocked epithelial-to-mesenchymal transition by interacting with β-catenin and inhibiting its nuclear translocation, which suppressed zinc finger E-box binding homeobox 1 (ZEB1) transcription. These results indicate that AJAP1 inhibits HCC metastasis, and is thus a potential therapeutic target for HCC treatment.